Yinnuo Pharmaceutical-B (02591) had a total market value of HK$653 million, of which shareholders deposited 84.2474 million shares with CITIC Securities Brokerage Hong Kong

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that according to the latest data from the Hong Kong Stock Exchange, on July 28, Yinnuo Pharmaceutical-B (02591) had a position change, with a total market value of HK$653 million, accounting for 20.05%. The company's shareholders deposited 84.2474 million shares with CITIC Securities Brokerage Hong Kong, increasing their shareholding ratio by 20.05%.

Yinnuo Pharmaceutical announced that according to previous announcements, the company expects to launch a phase IB clinical trial of the Group's esupaglutide α to treat adolescent obesity in July 2026. On July 28, 2026, the company successfully completed the enrollment and administration of the first patient in phase Ib of this clinical trial, and did not find any safety issues or adverse effects during the observation period.